![Approval success rates of drug candidates based on target, action, modality, application, and their combinations - Yamaguchi - 2021 - Clinical and Translational Science - Wiley Online Library Approval success rates of drug candidates based on target, action, modality, application, and their combinations - Yamaguchi - 2021 - Clinical and Translational Science - Wiley Online Library](https://ascpt.onlinelibrary.wiley.com/cms/asset/3d9bc3c2-afba-4025-8a1b-ca19c80a6c4b/cts12980-fig-0002-m.jpg)
Approval success rates of drug candidates based on target, action, modality, application, and their combinations - Yamaguchi - 2021 - Clinical and Translational Science - Wiley Online Library
![Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study - The Lancet Global Health Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study - The Lancet Global Health](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/86c8fa0e-bf67-43fd-acfb-a62be06bba00/gr1.jpg)
Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study - The Lancet Global Health
![Improving the odds of drug development success through human genomics: modelling study | Scientific Reports Improving the odds of drug development success through human genomics: modelling study | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-54849-w/MediaObjects/41598_2019_54849_Fig4_HTML.png)
Improving the odds of drug development success through human genomics: modelling study | Scientific Reports
Estimating Probabilities of Success of Vaccine and Other Anti-Infective Therapeutic Development Programs · Special Issue 1: COVID-19: Unprecedented Challenges and Chances
![Phase 0/microdosing approaches: time for mainstream application in drug development? | Nature Reviews Drug Discovery Phase 0/microdosing approaches: time for mainstream application in drug development? | Nature Reviews Drug Discovery](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41573-020-0080-x/MediaObjects/41573_2020_80_Fig1_HTML.png)
Phase 0/microdosing approaches: time for mainstream application in drug development? | Nature Reviews Drug Discovery
![Phase 0/microdosing approaches: time for mainstream application in drug development? | Nature Reviews Drug Discovery Phase 0/microdosing approaches: time for mainstream application in drug development? | Nature Reviews Drug Discovery](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41573-020-0080-x/MediaObjects/41573_2020_80_Fig2_HTML.png)
Phase 0/microdosing approaches: time for mainstream application in drug development? | Nature Reviews Drug Discovery
![Innovative Trial Designs in GI Drug Development: Why Trials Succeed and Fail—A Brief Report From 2018 Digestive Disease Week - Gastroenterology Innovative Trial Designs in GI Drug Development: Why Trials Succeed and Fail—A Brief Report From 2018 Digestive Disease Week - Gastroenterology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/ee4ad634-86e9-4d05-884a-09019e7b9401/gr1_lrg.jpg)
Innovative Trial Designs in GI Drug Development: Why Trials Succeed and Fail—A Brief Report From 2018 Digestive Disease Week - Gastroenterology
![Frontiers | Glaucoma Clinical Research: Trends in Treatment Strategies and Drug Development | Medicine Frontiers | Glaucoma Clinical Research: Trends in Treatment Strategies and Drug Development | Medicine](https://www.frontiersin.org/files/Articles/733080/fmed-08-733080-HTML/image_m/fmed-08-733080-g001.jpg)
Frontiers | Glaucoma Clinical Research: Trends in Treatment Strategies and Drug Development | Medicine
![Leveraging external data in the design and analysis of clinical trials in neuro-oncology - The Lancet Oncology Leveraging external data in the design and analysis of clinical trials in neuro-oncology - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/081014da-0892-4d75-8378-d5f9c963f700/gr1_lrg.jpg)
Leveraging external data in the design and analysis of clinical trials in neuro-oncology - The Lancet Oncology
![Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System - Value in Health Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System - Value in Health](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/745c29d5-f22c-48d8-9a1d-b30974b8eb56/gr3_lrg.jpg)